Acquisition of cgmp-grade GS-441524 for the treatment of covid-19
Ended Purchase Order Awarded Last action
- Contract number
- 75N95021P00063
- Awardee
-
Avista Pharma Solutions, Inc. UEI GRKKCA8LJNE4
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,086,294
Award facts
- Opportunity
-
- Acquisition of cGMP-grade GS-441524 for the Treatment of COVID-19 Solicitation · 75N95021Q00015 · Posted Nov 24, 2020
- Contract value 100% obligated
- $2,086,294.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27713, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,146 | |
| Supplemental Agreement for work within scope | $23,408 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $72,938 | |
| Supplemental Agreement for work within scope | $153,347 | |
| Supplemental Agreement for work within scope | $45,466 | |
| Supplemental Agreement for work within scope | $30,273 | |
| Additional Work (new agreement, FAR part 6 applies) | $308,385 | |
| Exercise an Option | $455,623 | |
| Original award | $998,000 |
About this award
The National Institute on Drug Abuse issued a purchase order to Avista Pharma Solutions, Inc. (doing business as Cambrex) on December 31, 2020, valued at $2,086,294.30 for the acquisition of cGMP-grade GS-441524 drug substance to support COVID-19 treatment research.
Place of performance is Durham, North Carolina. The order calls for manufacturing of cGMP-grade GS-441524 to support preclinical and Phase I clinical studies evaluating the drug's safety, tolerability, efficacy, pharmacokinetics, and optimal dose range for human use. The ultimate completion date is December 31, 2024. The solicitation was posted November 24, 2020 with proposals due December 1, 2020; award was made on a firm fixed-price basis without competitive discussions to the vendor offering best value.
Quick answers
Who was awarded contract 75N95021P00063?
75N95021P00063 was awarded to Avista Pharma Solutions, Inc. by National Institute on Drug Abuse (National Institutes of Health) on December 31, 2020.
How much is contract 75N95021P00063 worth?
The government has obligated $2,086,294 on 75N95021P00063.
Was contract 75N95021P00063 competed?
The extent of competition for 75N95021P00063 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award